Muittari A, Ahonen A, Kellomäki L, Kuusisto P, Lehtinen J, Veneskoski T
Clin Allergy. 1978 May;8(3):281-8. doi: 10.1111/j.1365-2222.1978.tb03225.x.
A study was made of the protective action of the anti-allergic drug ICI 74,917, a phenanthroline derivative, in specific allergen provocation tests and in combating clinical symptoms in thirteen asthmatic out-patients. It was found that ICI 74,917 was able to diminish allergen-induced bronchoconstriction significantly (P less than 0.01) during both the placebo period and during chronic treatment with ICI 74,917 for 4 weeks. The results obtained during these two periods did not differ significantly. There was not, however, any statistically significant difference in the symptom scores or PEF rates during the treatment with ICI 74,917 or placebo for 1 month. This may indicate that although ICI 74,197 is able to prevent bronchoconstriction in an allergen provocation test, it failed to improve asthma clinically. No signs of the phenomenon of tachyphylaxis were observed in the present study. The Student's t-test was used in the statistical analysis.
对一种抗过敏药物ICI 74,917（一种菲咯啉衍生物）在13名哮喘门诊患者的特异性过敏原激发试验以及对抗临床症状方面的保护作用进行了研究。结果发现，在安慰剂期以及用ICI 74,917进行4周的长期治疗期间，ICI 74,917均能显著减轻过敏原诱导的支气管收缩（P小于0.01）。这两个时期所获得的结果无显著差异。然而，在使用ICI 74,917或安慰剂治疗1个月期间，症状评分或呼气峰流速（PEF）率没有任何统计学上的显著差异。这可能表明，尽管ICI 74,197在过敏原激发试验中能够预防支气管收缩，但在临床上未能改善哮喘。在本研究中未观察到快速减敏现象的迹象。统计分析采用了学生t检验。
